MRK Merck & Co
- 127.999
- +2.459+1.96%
Merck & Co News
Moderna, Merck Say Vaccine Improved Survival in Patients With Deadly Skin Cancer
Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin cancer. Nearly 75% of patients who took the combination were alive without any signs or symptoms of their cancer returning at the 21⁄2-year mark. The overall survival rate of patients who took the vaccine in combination with Keytruda was 96% after 21⁄2 years.
Moderna And Merck Announced The First Presentation Of Results From A Planned Analysis From The Phase 2B KEYNOTE-942/mRNA-4157-P201 Study Of MRNA-4157 (V940) Plus Keytruda In Patients With Resected High-risk Melanoma Following Complete Resection (N=157)
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable i
Express News | Moderna & Merck Announce 3-Year Follow-up Data for Mrna-4157 (V940) in Combination With Keytruda (Pembrolizumab)
Express News | Moderna: Study Also Showed Meaningful Improvement in Distant Metastasis-Free Survival
Express News | Moderna: 2.5-Year Recurrence-Free Survival Rate of Mrna-4157 (V940) in Combination With Keytruda Was 74.8% Vs 55.6% for Keytruda Alone
Express News | Moderna: At Median Planned Follow-up of Phase 2B Study at 34.9 Months, Mrna-4157 (V940) With Keytruda Reduced Risk of Recurrence or Death by 49%
Express News | Moderna: Mrna-4157 (V940) in Combination With Keytruda Continued to Show Clinically Meaningful and Durable Improvement in Recurrence-Free Survival
Express News | Moderna: Initiated Phase 3 Studies in Patients With High-Risk Melanoma and Non-Small Cell Lung Cancer
Express News | Moderna: Safety Profile With Mrna-4157 (V940) in Combination With Keytruda in Keynote-942/Mrna-4157-P201 Remains Consistent With Primary Analysis
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial
Clinical-stage biotechnology company Immutep (ASX:IMM) entered into a clinical trial collaboration and supply agreement with Merck to evaluate eftilagimod alfa in combination with Merck's anti-PD-1 th
Emerging and Chinese Pharmas Playing Greater Role in Oncology Drug Development
FDA Oncology Chief Says International Clinical Trials Should Be Priority
Summit Lead Asset Approved in China for Lung Cancer
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Immunocore Touts Updated Phase 1 Results for Melanoma Asset Brenetafusp
Express News | NYSE Order Imbalance 736495.0 Shares on Buy Side
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company's stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced
Today's Analyst Rating | Melius Research Initiates Coverage on Microsoft With Target Price of $475, Itau Unibanco Upgrades Apple to Hold
May 31, Wall Street analysts have updated their stock ratings today including $Microsoft(MSFT.US)$ and $Apple(AAPL.US)$.
Summit -25%, Pares Gains as 'China-only' Trial Beats Merck's Keytruda
Dividend Roundup: Meta Platforms, Merck, Cigna, Halliburton, and More
Analysis
Price Target
No Data
